Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.
News|Articles|June 6, 2025
Pulmonology Month in Review: May 2025
Author(s)Victoria Johnson
Fact checked by: Abigail Brooks, MA
Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.
Advertisement
Advertisement
In May, the field of pulmonology witnessed significant advancements in the management of chronic respiratory diseases, highlighted by new clinical trial data presented at the American Thoracic Society (ATS) 2025 International Conference. These developments spanned a range of conditions, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary sarcoidosis, offering promising insights into emerging therapies and treatment strategies.
Related to this article
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Advertisement
Advertisement